Australian biopharmaceutical development company BioDiem Ltd (BDM) announced that it has entered into a licence agreement with the World Health Organization (WHO) for the LAIV influenza technology. With this agreement, BioDiem contributes to the WHO’s Global Pandemic Influenza Action Plan by supporting the transfer of an egg-based live attenuated influenza vaccine (LAIV) production technology to developing country manufacturers.
The agreement replaces the LAIV licence granted to the WHO by Nobilon International B.V. in 2009. The agreement is a non-exclusive licence designed to support wider distribution of the live attenuated influenza vaccine in developing countries. Whereas public sector usage under this agreement is royalty-free, royalties will flow to Biodiem directly from private sector sales.
As announced on 16 December 2010, BioDiem has already received US$248,310 in royalty payments through sales of Nasovac™ into the Indian private market by the Serum Institute of India. BioDiem’s CEO, Julie Phillips, said ‘BioDiem and its partner, the Institute of Experimental Medicine in Russia, have always maintained an excellent relationship with the WHO so it is of great benefit to us to have a more direct relationship with the WHO and to assist further access to the LAIV in developing countries in both public and private markets . BioDiem is also pleased to provide some funding to support the establishment of a back-up laboratory facility to provide reassortants to the WHO and its developing country licensees.’